Home › NDC Lookup › RxCUI directory › RxCUI 2534247

Tivozanib 1.34 MG Oral Capsule — RxCUI 2534247

RxNorm drug concept · Semantic clinical drug
RxCUI 2534247 Semantic clinical drug · SCD ● Current RxNorm concept 2 FDA products 4 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI2534247
Official nameTivozanib 1.34 MG Oral Capsule
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
Also known astivozanib (as tivozanib hydrochloride 1.5 MG) 1.34 MG Oral Capsule
FDA products mapped2
Package NDCs mapped4
Reported Medicaid activity (SDUD)60 prescriptions · 1 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Tivozanib: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • Fotivda (tivozanib) treats adults with advanced kidney cancer, called renal cell carcinoma, that has come back or stopped responding. It is used after at least two earlier treatmen...
  • Take one capsule by mouth once daily, with or without food. You take it for 21 days and then stop for 7 days, repeating in 28-day cycles. Swallow it whole with water and never open...
  • Common ones are tiredness, high blood pressure, diarrhea, less appetite, nausea, a hoarse voice, an underactive thyroid, cough and mouth sores. Tell us if they bother you. Your doc...
  • Call for chest pain, signs of a stroke, severe headache, seizures, vision changes, confusion, unusual bleeding, severe belly pain, or swelling and shortness of breath. These can be...
📖 Read our full Tivozanib guide →

🕸️ Concept Web — How Tivozanib 1.34 MG Oral Capsule Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Tivozanib 1.34 MG Oral Capsule RxCUI 2534247

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Tivozanib 2534233
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Fotivda 2534239
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Tivozanib Oral Capsule 2534237
    • Tivozanib Oral Product 2534235
    • Tivozanib Pill 2534236
    • Tivozanib Oral Capsule [Fotivda] 2534241
    • Fotivda Oral Product 2534242
    • Fotivda Pill 2534243
    • Oral Capsule 316965
    • Oral Product 1151131
    • +1 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Tivozanib 1.34 MG SCDC · 2534246
  • Tivozanib Oral Capsule SCDF · 2534237
  • Tivozanib Oral Product SCDG · 2534235
  • Tivozanib Pill SCDG · 2534236

Brand-Name Concepts

  • Tivozanib 1.34 MG Oral Capsule [Fotivda] SBD · 2534249
  • Tivozanib 1.34 MG [Fotivda] SBDC · 2534248
  • Tivozanib Oral Capsule [Fotivda] SBDF · 2534241
  • Fotivda Oral Product SBDG · 2534242
  • Fotivda Pill SBDG · 2534243
  • Fotivda BN · 2534239

📦 FDA Products & Package NDCs

2 products · 4 package NDCs
4 package NDCs map to RxCUI 2534247 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
45629-0089-01 1 BOTTLE, PLASTIC in 1 BAG (45629-089-01) / 21 CAPSULE in 1... FOTIVDA AVEO Pharmaceuticals, Inc. 2021-03-10
45629-0089-02 1 BOTTLE, PLASTIC in 1 CARTON (45629-089-02) / 21 CAPSULE i... FOTIVDA AVEO Pharmaceuticals, Inc. 2025-01-30
45629-0134-01 1 BOTTLE, PLASTIC in 1 BAG (45629-134-01) / 21 CAPSULE in 1... FOTIVDA AVEO Pharmaceuticals, Inc. 2021-03-10
45629-0134-02 1 BOTTLE, PLASTIC in 1 CARTON (45629-134-02) / 21 CAPSULE i... FOTIVDA AVEO Pharmaceuticals, Inc. 2025-01-30
Observed labelers: AVEO Pharmaceuticals, Inc. (4) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.